Aims: To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) AE metformin.
| INTRODUCTION
Type 2 diabetes mellitus (T2DM) is characterized by progressive loss of pancreatic β-cell insulin secretory function, with associated increases in hyperglycaemia and glucotoxicity. 1, 2 Therefore, most patients with T2DM require multiple glucose-lowering agents over time, preferably those with complementary mechanisms of action. 3, 4 Recent guidelines recommend early use of basal insulin as an option for patients with poor glycaemic control with oral therapies. [3] [4] [5] When glycaemic targets are not achieved with basal insulin, guidelines recommend uptitration of the basal insulin dose [3] [4] [5] or, if unsuccessful, intensification with additional therapies, including a glucagon-like peptide-1 receptor agonist (GLP-1RA), 3-5 prandial insulin, [3] [4] [5] sodium-glucose cotransporter-2 inhibitor (SGLT2i), 4, 5 or dipeptidyl peptidase-4 inhibitor (DPP-4i). 4 Among injectable options, adding a GLP-1RA to basal insulin therapy offers several advantages [6] [7] [8] [9] [10] [11] [12] over progressive intensification with prandial insulin up to 3 times daily. [13] [14] [15] [16] [17] GLP-1RAs reduce hyperglycaemia through differing and complementary mechanisms to exogenous insulin; they stimulate endogenous insulin synthesis/secretion in a glucosedependent manner, inhibit glucagon secretion, increase satiety, reduce food intake, and some slow gastric emptying. 2 GLP-1RAs achieve glycated haemoglobin (HbA1c) reductions similar to or greater than those achieved with prandial insulin, 18, 19 with the additional benefits of weight loss and low hypoglycaemia risk.
Among patients with inadequate glycaemic control despite basal insulin, real-world data indicate that treatment is often not intensified, either by continued uptitration of basal insulin or by addition of prandial insulin. 20, 21 The reasons are multifactorial, including concerns about hypoglycaemia and weight gain, requirement for frequent blood glucose self-monitoring and clinic visits, and patient dislike of multiple daily injections. Adding exenatide, the first in class GLP-1RA, twice daily (BID) improves glycaemic control without increased hypoglycaemia or weight gain among patients with uncontrolled T2DM
receiving basal insulin. 6 However, patients may wish to further reduce injection burden by adding a once-weekly (QW) GLP-1RA 22, 23 or a fixed-ratio basal insulin and GLP-1RA combination. 24, 25 Exenatide QW, which has good gastrointestinal tolerability, 26 probably resulting from the gradual release of exenatide from biodegradable microspheres, 27 has not been previously studied in combination with basal insulin.
This 28-week study investigated the efficacy and safety of adding exenatide QW or placebo for patients with T2DM who were inadequately controlled despite titrated basal insulin (insulin glargine
[IG]), with or without metformin.
| MATERIALS AND METHODS

| Study design and patients
DURATION-7 was a phase 3, randomized, double-blind, placebo-controlled, parallel-group study (ClinicalTrials.gov identifier: NCT02229383)
conducted at 126 centres in 6 countries (Hungary, Poland, Romania, Slovakia, South Africa and the USA) between September 2014 and August 2016. Eligible patients had T2DM and were ≥18 years of age and on a stable regimen comprising IG ≥20 units/d for ≥6 weeks, in combination with diet and exercise alone or with stable doses of metformin ≥1500 mg/d for >8 weeks AE a sulphonylurea. Additional inclusion criteria were HbA1c of 7.5% to 12.0% (59-108 mmol/mol) and fasting plasma glucose (FPG) <15.6 mmol/L (<280 mg/dL) at screening, and HbA1c of 7.0% to 10.5% (53-91 mmol/mol) at randomization. Complete inclusion and exclusion criteria are provided online in Table S1 in File S1.
The study included a screening visit, an 8-week IG titration phase, a 28-week double-blind treatment phase, and a 10-week safety follow-up period ( Figure S1 in File S1 (53-91 mmol/mol) after the IG titration phase were eligible for randomization.
All patients provided written informed consent. The study protocol was approved by institutional review boards at each site. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
| Randomization
Patients were randomized 1:1 to receive QW exenatide 2 mg or placebo injection in addition to their existing IG AE metformin regimen.
Randomization was performed centrally via an interactive web system and stratified by screening HbA1c of <9.0% or ≥9.0% (<75 or ≥75 mmol/mol) and prior sulphonylurea use. To ensure blinding, patients, investigators, study-site personnel and sponsor personnel did not have access to treatment codes or central laboratory FPG or HbA1c results for post-randomization visits.
| Procedures
Before administration of study drugs, patients (or caregivers) were instructed on product reconstitution and administration. Exenatide QW or matching placebo with microspheres (provided by the study sponsor) was self-administered QW by subcutaneous injection in the abdomen, thigh or upper arm at any time of day, immediately after dose preparation, using a single-dose syringe system. Stable metformin use was continued throughout the study for patients taking metformin at screening. During the study period, concomitant non-glucose-lowering medications were allowed at the investigator's discretion. The IG dose was titrated using the INITIATE algorithm (Table S2 in File S1) during both the IG titration and treatment periods, with planned adjustments as necessary. 
| Study endpoints
The primary endpoint was change in HbA1c from baseline to week Predefined cardiovascular AEs were adjudicated by an adjudication committee of independent cardiologists blinded to study treatment (Table S5 in File S1). For all study endpoints, change from baseline was calculated from the last non-missing assessment before the first dose of study drug at randomization. Hypothesis testing of primary and secondary efficacy endpoints followed a serial gatekeeping procedure to control for family-wise type I error rate (see Supplementary Methods online for a full description of testing sequence, File S1). Superiority of exenatide QW vs placebo was required at a 2-sided significance level of P < .05
| Statistical analyses
for sequential testing to proceed. Once a hypothesis test failed, no statistical significance could be claimed and P values were nominal for the remaining endpoints in the sequence. Nominal P values were reported for exploratory endpoints and were not adjusted for multiplicity. Statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, North Carolina).
3 | RESULTS
| Study population
Of 808 patients screened, 511 entered the 8-week IG titration phase Demographics and baseline characteristics were similar between treatment groups (Table 1) . Before study entry, in addition to insulin, most patients were treated with either metformin alone (51.6%) or metformin and a sulphonylurea (31.0%), with the remainder receiving a sulphonylurea alone (3.9%) or no additional glucose-lowering therapy (13.4%) ( Table 1) .
Treatment compliance was high across groups, with 92.7% and 93.9% of exenatide QW-treated patients and placebo-treated patients, respectively, using 80% to <120% of the dispensed study medication.
| Efficacy
| Glycaemic control
At screening, mean HbA1c, FPG and daily IG dose were similar between treatment groups (Table S6 in (Table S6 in File S1).
After randomization, exenatide QW was associated with a significantly greater HbA1c reduction from baseline to week 28 vs placebo [67 mmol/mol], respectively) ( Table 2) . A significant between-group difference was observed at week 4 and was maintained over the treatment period (Table 2 , Figure 2A ). Significantly more exenatide QW-treated patients vs placebo-treated patients achieved HbA1c
<7.0% (<53 mmol/mol) (32.5% vs 7.4%, respectively; P < .001) ( Figure 2C ). Figure 2D ). FPG reductions were apparent from week 2 ( Figure 2D) and were maintained over the 28-week treatment period. At week 28, exenatide QW was associated with a numerically larger decrease in mean 6-point self-monitored blood glucose vs placebo at all points, with the exception of before breakfast ( Figure S2 in File S1).
No significant difference was observed between groups for change in daily IG dose from baseline to week 28 (LSM difference, −2.0 units; 95% CI, −4.1 to +0.1; nominal P = .068) ( Table 2 ). In both groups, there was a small increase from baseline in the daily IG dose up to week 2, followed by stabilization through week 28 ( Figure 2E ). Figure 2F ). Reductions in body weight were apparent from week 8 ( Figure 2F ) and were maintained over the 28-week treatment period. A greater proportion of patients achieved ≥5%
body weight loss with exenatide QW than with placebo (6.9 percentage point difference; nominal P = .004) ( Table 2 ). More patients receiving exenatide QW vs placebo achieved HbA1c <7.0% Figure 2B ).
No significant differences were observed between exenatide QW and placebo for change from baseline to week 28 in waist circumference, DBP or fasting lipids (Table 2 ). There was a small numeric decrease with exenatide QW (−2.6 mm Hg) vs placebo (−0.7 mm Hg) in SBP (difference, −1.8 mm Hg; nominal P = .105).
| Patient-reported outcomes
Patients in both treatment groups reported improved treatment satisfaction as assessed by DTSQ-s total score; the improvement was greater with exenatide QW (Table S7 in File S1). At week 28, a numerically greater proportion of patients receiving exenatide QW vs placebo reported weight loss and improvement in all 9 areas assessed by the SHIELD-WQ-9 (Table S7 in File S1).
| Safety and tolerability
Exenatide QW, in combination with titrated IG, was associated with no unexpected safety findings (Table 3) .
No major hypoglycaemic events were reported in either treatment group (Table 3 ). Minor and "other" hypoglycaemic events, respectively, were observed in 5.6% and 29.3% of patients receiving exenatide QW and 5.6% and 27.7% of patients receiving placebo.
The most commonly reported AEs, other than hypoglycaemia, with exenatide QW vs placebo were urinary tract infection, nausea, diarrhoea and injection-site nodules (Table 3) . Serious AEs were reported in 4.7% and 4.8% of patients receiving exenatide QW and placebo, respectively. One patient receiving placebo died in the context of a severe pulmonary infection (specific cause of death unknown), and no deaths were reported in the exenatide QW group.
More exenatide QW-treated patients reported gastrointestinal
AEs than patients receiving placebo ( a MMRM analysis excluding measurements after initiation of rescue therapy or after premature discontinuation of study treatment.
b Cochran-Mantel-Haenszel analysis; missing data treated as non-responder.
c Nominal P value.
d Analysis of covariance excluding measurements after initiation of rescue therapy or after premature discontinuation of study treatment.
e A secondary endpoint. Not significant because of the testing hierarchy.
f MMRM analysis including measurements after initiation of rescue therapy and excluding measurements after premature discontinuation of study treatment.
g The analysis of covariance model used log-transformed triglyceride values. The reported effect estimates were converted back to the original scale. (Table S8 in File S1).
Most exenatide QW-treated patients (76.0%) developed antiexenatide antibodies at some point over the study period (Table S9 in 
18,19
In the current study, exenatide QW + IG was well tolerated, significantly improved a range of glycaemic measures, and reduced body weight vs placebo + IG. These improvements were observed without unexpected safety findings or increased hypoglycaemia vs placebo.
In the DURATION-7 study, injection-site-related AEs occurred in both the exenatide QW + IG and placebo + IG groups. Other sustained-release injectable drug formulations requiring in vivo degradation are also associated with injection-site reactions, 31 which might explain the occurrence of these reactions in both treatment groups, as both exenatide QW and placebo injections contained microspheres. However, the greater frequency of injection-site-related
AEs with exenatide-containing microspheres compared with placebocontaining microspheres observed in both the DURATION-7 and DURATION-8 studies, 32 especially among those with positive anti- Abbreviations: AE, adverse event; IG, insulin glargine; QW, once weekly; SAE, serious adverse event.
a Definitions of hypoglycaemia: major, loss of consciousness, seizure or coma resolving after glucagon or glucose administration or any event that required third-party assistance to resolve because of severe impairment in consciousness or behaviour, with glucose <3.0 mmol/L (<54 mg/dL); minor, any non-major event with symptoms consistent with hypoglycaemia and glucose <3.0 mmol/L (<54 mg/dL); other, any event not meeting the criteria for a major or minor event.
exenatide antibody status, suggests that, for exenatide QW, both ; however, caution is needed when making between-study comparisons because of the differences in study designs and populations. Consistent with the DURATION-7 study, adding a QW GLP-1RA to basal insulin resulted in significant improvements in glycaemic control and weight loss in both studies.
The HARMONY-6 study comprised a 4-to 8-week IG dose standardization/titration period, followed by a 52-week treatment period. 22 Despite recommendations of IG titration algorithms from both the HARMONY-6 and DURATION-7 studies, these were not consistently implemented in practice, as the mean IG dose increased only modestly after randomization in both groups (by 6-7 units at 26 weeks in HARMONY-6 22 and 2-4 units in DURATION-7).
The AWARD-9 23 study compared the addition of QW dulaglutide 1.5 mg or placebo to IG in patients with HbA1c of 7.0 to 10.5%
(53-91 mmol/mol). 23 In the DURATION-7 study, patients were randomized after IG titration had failed to lower HbA1c below 7.0%
(53 mmol/mol) following an increase in mean insulin doses from screening to baseline of 39 to~51 units, whereas IG dose titration began after randomization in the AWARD-9 study, thus maximizing the combined glucose-lowering actions of IG and dulaglutide.
While the DURATION-7, HARMONY-6 and AWARD-9 studies reported reduced glycaemia and body weight among GLP-1RA-treated patients, gastrointestinal AEs were higher with GLP-1RA treatment in all 3 studies. 22, 23 In DURATION-7, nausea, diarrhoea and vomiting occurred in 5.2%, 4.7% and 0.4% of exenatide QWtreated patients and 3.9%, 3.5% and 1.3% of placebo-treated patients, respectively. In HARMONY-6, nausea, diarrhoea and vomiting occurred in 11.2%, 13.0% and 6.7% of albiglutide-treated patients and 1.4%, 4.3% and 1.4% of lispro-treated patients, respectively. 22 In AWARD-9, these AEs occurred in 12.0%, 11.3% and 6.0% of dulaglutide-treated patients and 1.3%, 4.0% and 0.0% of placebotreated patients, respectively.
23
The DURATION-7 study has some limitations. Notably, IG titration was not strictly adhered to after randomization in all patients,
despite FPG values being above those specified in the INITIATE titration algorithm (4.0-5.5 mmol/L [72-99 mg/dL]). 28 Suboptimal titration was shown by smaller-than-expected increases in the IG dose, especially with placebo, despite elevated FPG levels. Had IG titration been more aggressive, the relative difference in the IG dose with exenatide QW vs placebo would be expected to have been larger. Although results across studies are not directly comparable, HbA1c reduction in the DURATION-7 study was similar to that in a separate study evaluating exenatide BID added to titrated IG, 6 whereas, in the DURATION-5 study, HbA1c reduction was significantly greater with exenatide QW vs exenatide BID. 33 This seemingly inconsistent finding regarding the glycaemic efficacy of exenatide QW vs BID is probably explained by suboptimal IG titration in the DURATION-7 study vs the exenatide BID + IG study (mean IG difference, 2 vs 7 units, 6 respectively) and by differences in study design (lack of an IG titration phase before randomization in the exenatide BID + IG study). 6 A similar suboptimal IG titration was observed in the HARMONY-6 study, 22 but also in other studies using various basal insulins. 34, 35 This probably reflects real-world clinical practice, where clinical inertia and concern about body weight gain and increased hypoglycaemia with insulin uptitration may result in physician/patient reluctance to adhere to strict algorithms. 20, 21 In summary, in patients with T2DM who were inadequately controlled despite titrated IG AE metformin, adding exenatide QW improved glycaemic measures and reduced body weight without major hypoglycaemia or unexpected safety findings. This suggests that exenatide QW represents a well-tolerated treatmentintensification option for patients with uncontrolled basal insulintreated T2DM.
